DEA
Description:
This handout discusses how a prescribing physician may prepare for a visit from the DEA. Such visits are required by law for physicians prescribing buprenorphine, and involve things such as prescription and dispensing records, and adherence to prescribing limits on number of patients.
Source:
PCSS
Tags:
Description:
This is a list of each state's prescription monitoring program contact information.
Source:
National Association of State Controlled Substances Authorities (NASCSA) (3 votes)
Tags:
Description:
These FAQs address common questions regarding prescription drug monitoring programs.
Source:
Drug Enforcement Agency (DEA) (4 votes)
Description:
This is the NASPER website which includes various information on the $60 million dollar 2005 grant to help states start or improve state-run prescription monitoring programs (PMPs).
Source:
American Society of Interventional Pain Physicians (3 votes)
Tags:
Description:
This 2006 document explains the Drug Enforcement Agency's (DEA) role in regulation of controlled substances and the physician's legal responsibility to prescribe controlled substances for legitimate medical purposes.
Source:
Drug Enforcement Agency (DEA) (3 votes)
Tags:
Description:
Answers to basic Medicaid and Medicare coverage questions from SAMSHA's FAQs on buprenorphine.
Source:
Substance Abuse and Mental Health Services Administration (SAMHSA) (3 votes)
Tags:
- Logistics of buprenorphine treatment
- Rules, regulations and recordkeeping
- Insurance and billing issues
- Patient education materials
- Cost of treatment
- DEA
- FAQ
- Insurance
- Medicaid
- Medicare
- Suboxone
- FAQ
- Misc. informational materials
- Becoming waivered
- Experienced prescriber
- Just became waivered
- Need to refer
- Setting up a practice
Description:
This survey of 375 physicians found that confidence addressing drug problems was positively associated with having a buprenorphine waiver.
Source:
Journal of General Internal Medicine, 2007 (4 votes)
Description:
This is the full text of Title 21, Chapter 13 of the US Code, which deals with drug abuse prevention and control.
Source:
Drug Enforcement Administration (DEA) (3 votes)
Tags:
Description:
This page links to the full text, summary, and physician waiver requirements under DATA 2000.
Source:
Substance Abuse and Mental Health Services Administration (SAMHSA) (3 votes)
Tags:
Description:
This form is for physicians to notify the DEA (through the Substance Abuse and Mental Health Services Administration) of their intent to use Schedule III, IV, or V drugs for treatment of opioid dependent patients.
Source:
The National Alliance of Advocates for Buprenorphine Treatment (NAABT) (3 votes)
Tags:
